Stablepharma completes first close of Series A raise with £2 million following announcements of high-profile partnershipsAscension Ventures announced as an investor in Stablepharma’s latest fund-raise
StablevaX™ - a vital complementary technology for vaccines
Our novel patented StablevaX™ technology can thermally stabilise and deliver a wide range of vaccines without the requirement for refrigeration. Stablepharma has developed a stabilised vaccine solution that could eliminate the need for the cold chain and enable stockpiling anywhere in the world.
StablevaX™ is designed to dramatically enhance the performance of existing and new vaccines. Stablepharma stands to revolutionise the vaccine industry, by helping shield vaccines from temperature-related deterioration and wastage.
StablevaX™ has shown strong in-vitro and in-vivo data on stabilising range of vaccines including Tetadif (Td) and naked COVID mRNA. Stablepharma R&D team believe that the StablevaX™ technology could be applicable to over 60 vaccines.
Latest Press Coverage StablevaX™
The WHO state that roughly 50% of vaccines are wasted due mostly to failures in the cold chain. Stablepharma aims to ensure that all vaccines can be removed from the refrigerated cold chain and stored for months or even years at room temperature.
StablevaX™ is a patented product that aims for enhanced thermostability, following WHO protocols
StablevaX™ technology aims to eliminate the need for refrigeration
StablevaX™ technology is designed with the aim of administering to patients without any change to current practice
Our white paper
StablevaX™ - a complementary technology for COVID-19 vaccines
In light of the ongoing Covid-19 pandemic, the challenge of equitable and efficient vaccine delivery has never been starker. Stablepharma believes that StablevaX™ could be a crucial complementary technology to currently available Covid-19 vaccines, especially those using mRNA-based approaches.